Researchers Uncover A Possible Cause Of Statin-Related Muscle Pain

For decades, millions of people taking statins have faced an uncomfortable trade-off: powerful protection against heart disease at the cost of persistent muscle pain. Now, researchers say they may have uncovered a key biological mechanism that helps explain why some patients develop these side effects.

A team from Columbia University and the University of Rochester reports that certain statins may destabilize a critical calcium channel inside muscle cells. When this microscopic "gate" begins to leak calcium, it can damage muscle fibers and trigger symptoms collectively known as statin-associated muscle symptoms (SAMS).

How Statins Protect The Heart

Statins are among the most widely prescribed medications in the world for preventing cardiovascular disease. They work by blocking an enzyme involved in cholesterol production in the liver, lowering levels of low-density lipoprotein (LDL), often referred to as "bad" cholesterol.

Reducing LDL cholesterol helps slow the buildup of fatty plaques inside arteries, lowering the risk of heart attacks and strokes. In the United States alone, roughly 40 million adults take statins, and their use continues to grow as medical guidelines increasingly emphasize early cholesterol management.

Why Some Patients Develop Muscle Symptoms

Despite their proven cardiovascular benefits, up to 10 percent of statin users report muscle-related side effects. These can include aching, weakness, tenderness, and cramps. In rare cases, symptoms may progress to rhabdomyolysis, a serious condition in which damaged muscle tissue breaks down and can injure the kidneys.

Because cardiovascular risks are often invisible, patients who develop persistent discomfort sometimes stop taking their medication, even when physicians strongly recommend continuing treatment. For years, researchers have debated how often statins truly cause muscle symptoms and what biological processes might be responsible.

The Role Of A Tiny Calcium Channel

The new study focuses on a protein known as ryanodine receptor 1 (RyR1), which is located on the sarcoplasmic reticulum surrounding muscle fibers. RyR1 acts as a calcium channel, releasing calcium ions that are essential for normal muscle contraction.

Using cryo-electron microscopy, researchers were able to visualize how simvastatin and several related statins interact directly with RyR1. Their findings suggest that the drugs may hold the channel open longer than normal, allowing calcium to leak continuously into muscle cells rather than remaining under tight biological control.

Over time, excess calcium inside muscle cells can activate destructive enzymes and damage muscle fibers. In laboratory mice, these calcium leaks were associated with weakness and other features that resemble statin-associated muscle symptoms seen in humans.

Who May Be Most Vulnerable

The harmful effects appeared to be especially pronounced in animals carrying genetic mutations that already reduce RyR1 stability. In humans, such mutations are associated with rare disorders including malignant hyperthermia and certain inherited muscle diseases.

For individuals with underlying RyR1 vulnerabilities, statin-induced calcium leaks could potentially worsen existing muscle weakness or trigger more severe episodes of muscle damage. The findings raise the possibility that some patients may be genetically predisposed to statin intolerance.

Potential New Treatment Approaches

The research points to two possible strategies for reducing muscle side effects while preserving the cardiovascular benefits of statins.

One option would be to redesign statin molecules so they no longer interact with RyR1 while still effectively lowering cholesterol production in the liver.

Another approach focuses on stabilizing the calcium channel itself. In mouse experiments, an investigational class of compounds known as Rycals helped seal the leaky channels and prevented simvastatin-related muscle weakness. Although still experimental, the results suggest that future add-on therapies may help patients remain on statin treatment.

What Patients Should Know

Researchers caution that calcium leakage is unlikely to explain every case of statin-associated muscle symptoms. Muscle pain can have many causes, and clinical trials have shown that some symptoms occur even among patients taking placebo medications.

Nevertheless, the discovery provides scientists with a concrete biological target for future research. It may eventually lead to blood tests or genetic screening tools capable of identifying individuals at greater risk for statin-related muscle problems.

For now, cardiology guidelines continue to emphasize that most patients tolerate statins well and receive substantial protection against heart disease.

Patients who develop muscle symptoms are advised not to stop treatment abruptly. Instead, they should discuss the issue with their healthcare provider. Possible solutions include lowering the dose, switching to a different statin, using intermittent dosing schedules, or combining lower-dose statins with non-statin cholesterol-lowering therapies such as ezetimibe or PCSK9 inhibitors.

A Step Toward Safer Cholesterol Treatment

The study, published in the Journal of Clinical Investigation, adds an important piece to a long-standing medical puzzle.

While additional human studies will be needed to confirm the findings, the research opens the door to safer statin designs, personalized risk assessment, and targeted therapies that could help more high-risk patients stay on life-saving cholesterol treatment without sacrificing quality of life.